By treating patients with oral liquid atorvastatin to assist adherence, benefits for each Integrated Care Board (ICB) can potentially be achieved. These include both cost savings and greater consideration for vulnerable patient groups, such as those with intellectual disabilities (ID).
Leading care for vulnerable patients
The Atorvastatin Health Economics Calculator has been developed after consideration of conditions that switching to licensed liquid atorvastatin may affect, and making certain assumptions of the consequences of doing so. The calculator has been reviewed and evaluated by Health Economics Consulting at the University of East Anglia. Rosemont Pharmaceuticals has paid the University of East Anglia a fee for this service.
You are invited to use the calculator to see what level of savings might be achieved in your ICB. Receiving the results of potential savings direct to your inbox is simple.
All you need to do is: